Study of (Telintra速) in Non-Del(5q) Myelodysplastic Syndrome
This is a multicenter, single arm open label Phase 2b Study of oral ezatiostat (Telintra速) in Patients who are RBC tranfusion dependent, Low to INT-1 IPSS risk, non-del (5q) Myelodysplastic Syndrome (MDS).
Myelodysplastic Syndrome (MDS)
DRUG: ezatiostat hydrochloride (Telintra速)
Hematologic Improvement-Erythroid (HI-E) rate, Hematologic Improvement response will be assessed per the IWG MDS response criteria (2006), At 8 weeks of treatment|Hematologic Improvement-Erythroid (HI-E) rate, Hematologic Improvement response will be assessed per the IWG MDS response criteria (2006), At 16 weeks of treatment|Hematologic Improvement-Erythroid (HI-E) rate, Hematologic Improvement response will be assessed per the IWG MDS response criteria (2006), At 24 weeks of treatment|Hematologic Improvement-Erythroid (HI-E) rate, Hematologic Improvement response will be assessed per the IWG MDS response criteria (2006), At 32 weeks of treatment
RBC Transfusion independence (TI) rate, At 4, 8, 12, 16, 20, 24, 28 & 32 weeks of treatment|Hematologic Improvement-Neutrophil (HI-N) rate, Hematologic Improvement response will be assessed per the IWG MDS response criteria (2006), At 8, 16, 24, & 32 weeks of treatment|Hematologic Improvement-Platelet (HI-P) rate, Hematologic Improvement response will be assessed per the IWG MDS response criteria (2006), At 8, 16, 24, & 32 weeks of treatment|Unilineage, bilineage, trilineage, and overall HI response rate, 2 years|Cytogenetic response rate, 16 weeks, 48 weeks and at the time of first HI response|Duration of response, 2 years|Safety of ezatiostat in this MDS population, Recording and grading of AEs using NCI-CTCAE v4.03, At 4, 8, 12, 16, 20, 24, 28 & 32 weeks of treatment|Evaluation of the relationship between HI-E response, gene expression profiling and response-related variables, 2 years
This is a multicenter, single arm open label Phase 2b Study of oral ezatiostat (Telintra速) in Patients who are RBC tranfusion dependent, Low to INT-1 IPSS risk, non-del (5q) Myelodysplastic Syndrome (MDS).